Highland Capital Management (Texas)’s Heron Therapeutics HRTX Stock Holding History

Highland Capital Management (Texas)’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	$29.9M	Buy	1,606,942 +561,550	+54%	+$11.2M	1.75%	12
2019 Q1	$25.6M	Sell	1,045,392 -14,400	-1%	-$377K	1.59%	10
2018 Q4	$27.5M	Buy	1,059,792 +214,750	+25%	+$5.9M	2.11%	10
2018 Q3	$26.7M	Sell	845,042 -58,815	-7%	-$2.19M	1.48%	12
2018 Q2	$35.1M	Sell	903,857 -587,712	-39%	-$18.7M	1.99%	9
2018 Q1	$41.2M	Sell	1,491,569 -2,606	-0.2%	-$59.1K	2.12%	6
2017 Q4	$27M	Sell	1,494,175 -7,002	-0.5%	-$114K	1.24%	17
2017 Q3	$24.2M	Sell	1,501,177 -110,925	-7%	-$1.74M	1.07%	14
2017 Q2	$22.3M	Sell	1,612,102 -32,050	-2%	-$464K	0.95%	20
2017 Q1	$24.7M	Buy	1,644,152 +81,335	+5%	+$1.13M	1.25%	16
2016 Q4	$20.5M	Buy	1,562,817 +912,086	+140%	+$14.3M	0.96%	27
2016 Q3	$11.2M	Buy	+650,731	New	+$12.1M	0.34%	59

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Highland Capital Management (Texas)'s HRTX Position: Q2 2019 in Review

Highland Capital Management (Texas) increased its Heron Therapeutics (HRTX) stake by 54% in Q2 2019, buying an estimated $11.2M and bringing the position to 1,606,942 shares worth $29.9M. The position accounts for 1.75% of the portfolio, ranked #12.

Highland Capital Management (Texas) first reported a position in HRTX in Q3 2016 and has held it in 12 quarters since. The position peaked at $41.2M in Q1 2018. 176 funds tracked by Wall St. Rank hold HRTX as of Q2 2019.

Highland Capital Management (Texas) held 1,606,942 shares of Heron Therapeutics worth $29.9M as of Q2 2019.
Highland Capital Management (Texas) bought 561,550 Heron Therapeutics shares in Q2 2019, an estimated $11.2M.
Heron Therapeutics made up 1.75% of Highland Capital Management (Texas)'s portfolio in Q2 2019, its #12 holding.
Highland Capital Management (Texas) first reported a position in Heron Therapeutics in Q3 2016 and has held it in 12 quarters since.
Highland Capital Management (Texas)'s Heron Therapeutics position peaked at $41.2M in Q1 2018.
176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2019.

Based on Highland Capital Management (Texas)'s 13F filing for Q2 2019, filed 14 Aug 2019.